122 related articles for article (PubMed ID: 37985430)
21. Hepatocyte growth factor renders BRAF mutant human melanoma cell lines resistant to PLX4032 by downregulating the pro-apoptotic BH3-only proteins PUMA and BIM.
Rohrbeck L; Gong JN; Lee EF; Kueh AJ; Behren A; Tai L; Lessene G; Huang DC; Fairlie WD; Strasser A; Herold MJ
Cell Death Differ; 2016 Dec; 23(12):2054-2062. PubMed ID: 27689874
[TBL] [Abstract][Full Text] [Related]
22. Vemurafenib resistance increases melanoma invasiveness and modulates the tumor microenvironment by MMP-2 upregulation.
Sandri S; Faião-Flores F; Tiago M; Pennacchi PC; Massaro RR; Alves-Fernandes DK; Berardinelli GN; Evangelista AF; de Lima Vazquez V; Reis RM; Maria-Engler SS
Pharmacol Res; 2016 Sep; 111():523-533. PubMed ID: 27436149
[TBL] [Abstract][Full Text] [Related]
23. Synergistic combination of novel tubulin inhibitor ABI-274 and vemurafenib overcome vemurafenib acquired resistance in BRAFV600E melanoma.
Wang J; Chen J; Miller DD; Li W
Mol Cancer Ther; 2014 Jan; 13(1):16-26. PubMed ID: 24249714
[TBL] [Abstract][Full Text] [Related]
24. Oral lipid nanocomplex of BRD4 PROteolysis TArgeting Chimera and vemurafenib for drug-resistant malignant melanoma.
Saraswat A; Vartak R; Hegazy R; Fu Y; Rao TJR; Billack B; Patel K
Biomed Pharmacother; 2023 Dec; 168():115754. PubMed ID: 37871557
[TBL] [Abstract][Full Text] [Related]
25. Chemically Linked Vemurafenib Inhibitors Promote an Inactive BRAF
Grasso M; Estrada MA; Ventocilla C; Samanta M; Maksimoska J; Villanueva J; Winkler JD; Marmorstein R
ACS Chem Biol; 2016 Oct; 11(10):2876-2888. PubMed ID: 27571413
[TBL] [Abstract][Full Text] [Related]
26. Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma.
Ravnan MC; Matalka MS
Clin Ther; 2012 Jul; 34(7):1474-86. PubMed ID: 22742884
[TBL] [Abstract][Full Text] [Related]
27. Targeting the Proteasome-Associated Deubiquitinating Enzyme USP14 Impairs Melanoma Cell Survival and Overcomes Resistance to MAPK-Targeting Therapies.
Didier R; Mallavialle A; Ben Jouira R; Domdom MA; Tichet M; Auberger P; Luciano F; Ohanna M; Tartare-Deckert S; Deckert M
Mol Cancer Ther; 2018 Jul; 17(7):1416-1429. PubMed ID: 29703842
[TBL] [Abstract][Full Text] [Related]
28. Pharmacodynamic characterization of the efficacy signals due to selective BRAF inhibition with PLX4032 in malignant melanoma.
Tap WD; Gong KW; Dering J; Tseng Y; Ginther C; Pauletti G; Glaspy JA; Essner R; Bollag G; Hirth P; Zhang C; Slamon DJ
Neoplasia; 2010 Aug; 12(8):637-49. PubMed ID: 20689758
[TBL] [Abstract][Full Text] [Related]
29. Differential inhibition of ex-vivo tumor kinase activity by vemurafenib in BRAF(V600E) and BRAF wild-type metastatic malignant melanoma.
Tahiri A; Røe K; Ree AH; de Wijn R; Risberg K; Busch C; Lønning PE; Kristensen V; Geisler J
PLoS One; 2013; 8(8):e72692. PubMed ID: 24023633
[TBL] [Abstract][Full Text] [Related]
30. HI-511 overcomes melanoma drug resistance
Chang X; Zhang T; Wang Q; Rathore MG; Reddy K; Chen H; Shin SH; Ma WY; Bode AM; Dong Z
Theranostics; 2020; 10(21):9721-9740. PubMed ID: 32863956
[No Abstract] [Full Text] [Related]
31. M-CSF as a therapeutic target in BRAF
Barceló C; Sisó P; de la Rosa I; Megino-Luque C; Navaridas R; Maiques O; Urdanibia I; Eritja N; Soria X; Potrony M; Calbet-Llopart N; Puig S; Matías-Guiu X; Martí RM; Macià A
Br J Cancer; 2022 Oct; 127(6):1142-1152. PubMed ID: 35725813
[TBL] [Abstract][Full Text] [Related]
32. Concurrent MEK and autophagy inhibition is required to restore cell death associated danger-signalling in Vemurafenib-resistant melanoma cells.
Martin S; Dudek-Perić AM; Maes H; Garg AD; Gabrysiak M; Demirsoy S; Swinnen JV; Agostinis P
Biochem Pharmacol; 2015 Feb; 93(3):290-304. PubMed ID: 25529535
[TBL] [Abstract][Full Text] [Related]
33. Resistance to BRAF Inhibitors: EZH2 and Its Downstream Targets as Potential Therapeutic Options in Melanoma.
Uebel A; Kewitz-Hempel S; Willscher E; Gebhardt K; Sunderkötter C; Gerloff D
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768289
[TBL] [Abstract][Full Text] [Related]
34. Mitochondrial complex I inhibitor deguelin induces metabolic reprogramming and sensitizes vemurafenib-resistant BRAF
Carpenter EL; Chagani S; Nelson D; Cassidy PB; Laws M; Ganguli-Indra G; Indra AK
Mol Carcinog; 2019 Sep; 58(9):1680-1690. PubMed ID: 31211467
[TBL] [Abstract][Full Text] [Related]
35. A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib.
Graziani G; Artuso S; De Luca A; Muzi A; Rotili D; Scimeca M; Atzori MG; Ceci C; Mai A; Leonetti C; Levati L; Bonanno E; Tentori L; Caccuri AM
Biochem Pharmacol; 2015 May; 95(1):16-27. PubMed ID: 25795251
[TBL] [Abstract][Full Text] [Related]
36. Characterization of Vemurafenib-Resistant Melanoma Cell Lines Reveals Novel Hallmarks of Targeted Therapy Resistance.
Radić M; Vlašić I; Jazvinšćak Jembrek M; Horvat A; Tadijan A; Sabol M; Dužević M; Herak Bosnar M; Slade N
Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36077308
[TBL] [Abstract][Full Text] [Related]
37. Targeting the hedgehog transcription factors GLI1 and GLI2 restores sensitivity to vemurafenib-resistant human melanoma cells.
Faião-Flores F; Alves-Fernandes DK; Pennacchi PC; Sandri S; Vicente AL; Scapulatempo-Neto C; Vazquez VL; Reis RM; Chauhan J; Goding CR; Smalley KS; Maria-Engler SS
Oncogene; 2017 Mar; 36(13):1849-1861. PubMed ID: 27748762
[TBL] [Abstract][Full Text] [Related]
38. Salmonella typhimurium A1-R targeting of a chemotherapy-resistant BRAF-V600E melanoma in a patient-derived orthotopic xenograft (PDOX) model is enhanced in combination with either vemurafenib or temozolomide.
Kawaguchi K; Igarashi K; Murakami T; Kiyuna T; Zhao M; Zhang Y; Nelson SD; Russell TA; Dry SM; Singh AS; Chmielowski B; Li Y; Unno M; Eilber FC; Hoffman RM
Cell Cycle; 2017 Jul; 16(13):1288-1294. PubMed ID: 28622068
[TBL] [Abstract][Full Text] [Related]
39. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance.
Das Thakur M; Salangsang F; Landman AS; Sellers WR; Pryer NK; Levesque MP; Dummer R; McMahon M; Stuart DD
Nature; 2013 Feb; 494(7436):251-5. PubMed ID: 23302800
[TBL] [Abstract][Full Text] [Related]
40. An autophagy-driven pathway of ATP secretion supports the aggressive phenotype of BRAF
Martin S; Dudek-Peric AM; Garg AD; Roose H; Demirsoy S; Van Eygen S; Mertens F; Vangheluwe P; Vankelecom H; Agostinis P
Autophagy; 2017 Sep; 13(9):1512-1527. PubMed ID: 28722539
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
